Pemetrexed and Cisplatin for Malignant Pleural Mesothelioma: A New Standard of Care?
- 15 July 2003
- journal article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (14) , 2629-2630
- https://doi.org/10.1200/jco.2003.02.043
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2003
- Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesotheliomaBritish Journal of Cancer, 2002
- A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesotheliomaThe Journal of Thoracic and Cardiovascular Surgery, 2001
- Important prognostic factors in patients with malignant pleural mesothelioma, managed surgicallyThe Annals of Thoracic Surgery, 1999
- Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patientsThe Journal of Thoracic and Cardiovascular Surgery, 1999
- Cisplatin and Gemcitabine Treatment for Malignant Mesothelioma: A Phase II StudyJournal of Clinical Oncology, 1999
- A Review of Chemotherapy Trials for Malignant MesotheliomaChest, 1998